Nearly 15% of all invasive breast cancers are triple-negative breast cancers (TNBC), a very aggressive form (2, 3) in which estrogen-, progesterone, and human epidermal growth factor receptor 2 (HER2) expression is absent, which necessitates finding novel targets to tackle TNBC. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.